George McBride
Founder
Clerkenwell Health
Clerkenwell Health is a clinical research organization specializing in psychedelic therapies, utilizing a vetted patient database and experienced investigators to enhance access to psychiatric and central nervous system (CNS) trials. The company addresses the need for effective treatment options in psychiatric conditions by streamlining clinical development processes and improving patient recruitment.
- Biotechnology
- Healthcare Technology
Updated 7 months ago
Funding
Raised to date
$3.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Developing effective treatments for psychiatric and central nervous system (CNS) conditions is hindered by challenges in patient recruitment and the complexities of clinical trial design, particularly for psychedelic therapies. Traditional clinical research organizations often lack the specialized expertise and patient access needed to efficiently conduct these trials.
Solution
Clerkenwell Health is a clinical research organization (CRO) specializing in psychiatric and CNS trials, offering enhanced patient access and integrated clinical solutions to accelerate the development of new treatments. The company leverages a vetted database of over 45,000 UK patients and a network of experienced investigators to streamline patient recruitment and improve trial efficiency. Clerkenwell Health provides expertise in trial design, regulatory affairs, and therapist training, specifically tailored for psychedelic-assisted therapies. By focusing on these specialized areas, Clerkenwell Health aims to facilitate faster, more effective clinical trials and improve outcomes for patients with mental health and CNS disorders.
Target Audience
Clerkenwell Health primarily serves drug developers, pharmaceutical companies, and other CROs focused on psychiatric and CNS treatments, particularly those involving psychedelic therapies.
Features
- Vetted database of over 45,000 UK patients for rapid recruitment
- Experienced investigators with expertise in 20+ psychiatric and CNS indications
- Dedicated therapist database of over 1,000 professionals
- Expertise in psychedelic-assisted therapy trial design and execution
- Integrated clinical solutions for enhanced protocol adherence and data quality
- In-house clinical research facility
- Therapist training programs
- Regulatory affairs support